Research programme: anti-cancer therapeutics - Zestagen

Drug Profile

Research programme: anti-cancer therapeutics - Zestagen

Alternative Names: mAb 4C5; ZSG 101; ZSG 102; ZSG 103

Latest Information Update: 29 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hellenic Pasteur Institute
  • Developer Hellenic Pasteur Institute; Zestagen
  • Class Monoclonal antibodies
  • Mechanism of Action HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Breast cancer; Malignant melanoma; Non-small cell lung cancer

Most Recent Events

  • 28 Nov 2016 Early research in Non-small cell lung cancer in Switzerland (unspecified route)
  • 28 Nov 2016 Zestagen plans a phase I trial before November 2016
  • 25 Nov 2016 Research programme: anti-cancer therapeutics - Zestagen is seeking series A financing as of 25 Nov 2016. http://www.zestagen.com/index.html; 3210352
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top